← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $258B	2,313	-29	-1%	$203B
2	2 Danaher DHR $163B	2,041	-41	-2%	$166B
3	3 Novartis NVS $286B	1,137	-9	-0.8%	$18.3B
4	4 Regeneron Pharmaceuticals REGN $82B	1,095	+17	+2%	$64.5B
5	5 Illumina ILMN $40.5B	1,041	-24	-2%	$47.8B
6	6 Agilent Technologies A $49.5B	933	-51	-5%	$34.7B
7	7 Charles River Laboratories CRL $14.6B	644	-63	-9%	$13.5B
8	8 Revvity RVTY $17.3B	642	-7	-1%	$19.2B
9	9 DELISTED CATALENT, INC. CTLT	536	-26	-5%	$19.9B
10	10 CRISPR Therapeutics CRSP $4.98B	446	0	0%	$3.47B
11	11 Alnylam Pharmaceuticals ALNY $31.3B	444	+9	+2%	$18.6B
12	12 ARK Genomic Revolution ETF ARKG $2.09B	388	-74	-16%	$1.09B
13	13 Azenta AZTA $1.6B	383	-18	-4%	$6.14B
14	14 Guardant Health GH $22.3B	356	-40	-10%	$6.12B
15	15 Intellia Therapeutics NTLA $1.59B	349	-23	-6%	$4.71B
16	16 Ionis Pharmaceuticals IONS $7.33B	334	-7	-2%	$4.63B
17	17 Sarepta Therapeutics SRPT $1.88B	329	-15	-4%	$5.71B
18	NVTA 18 DELISTED Invitae Corporation NVTA	316	-12	-4%	$1.6B
19	19 10x Genomics TXG $9.43B	314	-51	-14%	$6.3B
20	20 Bruker BRKR $8.61B	311	-16	-5%	$6.83B
21	21 Arrowhead Research ARWR $8.26B	307	-3	-1%	$3.19B
22	22 Qiagen QGEN $9.53B	293	-8	-3%	$6.39B
23	23 Fulgent Genetics FLGT $587M	275	-23	-8%	$759M
24	24 Editas Medicine EDIT $375M	256	-50	-16%	$862M
25	25 Fate Therapeutics FATE $231M	250	0	0%	$3.92B